SPRYD4: A Potential Drug Target and Biomarker for Diseases (G283377)

Target Name: SPRYD4

NCBI ID: G283377

SPRYD4

Other Name(s): SPRY4_HUMAN | SPRY domain-containing protein 4 | SPRY domain containing 4

SPRYD4: A Potential Drug Target and Biomarker for Diseases

SPRYD4 (SPRY4-HUMAN) is a protein that is expressed in human tissues and is known for its role in the development and progression of various diseases, including cancer. The SPRYD4 gene has also been identified as a potential drug target and biomarker for several diseases.

SPRYD4 is a member of the SPRY gene family, which is known for its role in the development and regulation of sensory neurons. The SPRYD4 gene is located on chromosome 12 and has been shown to encode a protein that is involved in several cellular processes, including cell signaling, DNA replication, and stress response.

SPRYD4 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of SPRYD4 are associated with poor prognosis in patients with pancreatic cancer, a highly aggressive form of cancer that is difficult to treat. Additionally, SPRYD4 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

SPRYD4 has also been identified as a potential drug target for several diseases. For example, SPRYD4 has been shown to be involved in the development of neuropsychiatric diseases, such as depression and anxiety. Additionally, SPRYD4 has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In addition to its potential as a drug target, SPRYD4 has also been identified as a potential biomarker for several diseases. For example, studies have shown that SPRYD4 levels are elevated in the brains of patients with Alzheimer's disease, a neurodegenerative disease. Additionally, SPRYD4 has been shown to be involved in the development of cancer, which could make it an attractive biomarker for cancer detection and treatment.

Overall, SPRYD4 is a protein that has the potential to be a drug target and biomarker for several diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: SPRY Domain Containing 4

The "SPRYD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPRYD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets